We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The FDA slammed Hospira’s sterile drug facility in McPherson, Kansas, after finding the same violations during recent inspections that were flagged during earlier probes. Read More
Serious deficiencies in sterile drug production at Greenpark Compounding in Houston, Texas, may put patients at risk, the FDA said in a warning letter to the compounder. Read More
The FDA sent a warning letter listing a slew of violations to StemGenex Biologic Laboratories, following a January 16-26 inspection of its San Diego, California, facility. Read More
The FDA placed valsartan manufacturer Zhejiang Huahai on an import alert and the EMA issued a noncompliance statement barring Europe’s drugmakers from using the company’s API in their blood pressure products. Read More